Navigation Links
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Date:2/20/2009

BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Announces Issuance of U.S. Patent for ITMN-191
2. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
3. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Release Third Quarter 2008 Financial Results on November 6
8. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
9. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. InterMune to Present at Canaccord Adams Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:4/23/2014)... Aires yesterday, Argentina joins the European Molecular Biology ... move strengthens the ties between the European and ... scientists access to EMBL,s world-class facilities and programs, ... its inception, fostering excellent life science research and ... of EMBL,s mission," says EMBL Director General Iain ...
(Date:4/23/2014)... cli-fi, is a newly coined term for novels and films ... from University of Copenhagen shows how these fictions serve as ... consequences of climate change and imagine other living conditions. ... changes in the atmosphere; it is also a cultural phenomenon ... read and the films we see. And there are so ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Impact of whooping cough vaccination revealed 2
... AGA Research Foundation and Horizon Pharma further establish their ... the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the ... third year, this competition continues to grow in popularity ... in basic and clinical research," said Nicholas F. LaRusso, ...
... declining worldwide and a major cause is a deadly fungus ... shows they can also die from this pathogen, contrary to ... spreads the disease. When researchers raised the frogs from ... strain of this pathogen, Batrachochytrium dendrobatidis , also called ...
... news release is available in French . ... in older mice with Alzheimer,s disease can be reversed with treatment. ... - The Neuro, at McGill University and at Universit de Montral ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory and ...
Cached Biology News:Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... RNase ONE Ribonuclease is a 27kDa periplasmic ... degradation of RNA to cyclic nucleotide monophosphate ... degradation of these intermediates to 3-NMPs (1). ... few known RNases that can cleave a ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
Biology Products: